1
|
Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D, Robertson CL, Mukhopadhyay ND, Fisher PB, Sarkar D. Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio 2014; 4:353-61. [PMID: 24918049 PMCID: PMC4050181 DOI: 10.1016/j.fob.2014.03.012] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 03/13/2014] [Accepted: 03/27/2014] [Indexed: 12/29/2022] Open
Abstract
Staphylococcal nuclease domain containing-1 (SND1) is overexpressed in human hepatocellular carcinoma (HCC) patients and promotes tumorigenesis by human HCC cells. We now document that SND1 increases angiotensin II type 1 receptor (AT1R) levels by increasing AT1R mRNA stability. This results in activation of ERK, Smad2 and subsequently the TGFβ signaling pathway, promoting epithelial-mesenchymal transition (EMT) and migration and invasion by human HCC cells. A positive correlation was observed between SND1 and AT1R expression levels in human HCC patients. Small molecule inhibitors of SND1, alone or in combination with AT1R blockers, might be an effective therapeutic strategy for late-stage aggressive HCC.
Collapse
Key Words
- ACE, angiotensin-I converting enzyme
- ACE-I, ACE inhibitors
- AT1R
- AT1R, angiotensin II type 1 receptor
- EMT, epithelial–mesenchymal transition
- FDR, false discovery rate
- HCC, human hepatocellular carcinoma
- Invasion
- LP, losartan potassium
- MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- NASH, non-alcoholic steatohepatitis
- PAI-1
- PAI-1, plasminogen activator inhibitor-1
- RISC, RNA-induced silencing complex
- SND1
- SND1, Staphylococcal nuclease domain containing-1
- TGFβ
Collapse
Affiliation(s)
- Prasanna K. Santhekadur
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Maaged Akiel
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Luni Emdad
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Rachel Gredler
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Jyoti Srivastava
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Devaraja Rajasekaran
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Chadia L. Robertson
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Nitai D. Mukhopadhyay
- Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Paul B. Fisher
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA 23298, United States
| | - Devanand Sarkar
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, United States
- Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States
- VCU Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA 23298, United States
- Corresponding author at: Department of Human and Molecular Genetics, Virginia Commonwealth University, 1220 East Broad St, PO Box 980035, Richmond, VA 23298, United States. Tel.: +1 (804) 827 2339; fax: +1 (804) 628 1176.
| |
Collapse
|